Goldman Sachs has a reputation for helping its clients ward off hostile takeover attempts. But since Allergan brought the firm on to defend against Valeant's unsolicited bid, Goldman's been rather quiet–prior involvement with Valeant may have something to do with it, <em>The New York Times</em> reports.
written on 13.06.2014
NYT: Goldman Sachs caught in the middle of Valeant, Allergan takeover fight
